AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal

Sees Potential Beyond Vaccines

 
• By Andrew McConaghie
  
AstraZeneca
The partners hope VaxEquity's self-ampliftying RNA technology can serve as the basis of therapies as well as vaccines.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip